QIoT
QIoT is a Scotland-based digital health company offering an AI-powered connected asthma management platform that combines a smart inhaler cap, a freemium mobile app, predictive analytics, and a Digital Therapeutics module for NHS and private healthcare providers.
- Company typePrivate
- Founded2018
- HeadquartersPaisley, United Kingdom
- Headcount1–10
- GTM typeB2B and B2C
- OfferingSoftware
What QIoT does
QIoT is a Scotland-based digital health company, founded in 2018 and headquartered in Paisley/Glasgow, that has built an AI-powered connected asthma management platform. The product suite combines a hardware Connected Inhaler Cap (which records the time, frequency, and location of inhaler activations) with a consumer-facing mobile application distributed on Google Play and Apple App Store in both free and paid versions. The underlying AI Healthcare Platform applies predictive analytics to anticipate asthma exacerbations and provides personalised insights by integrating medication usage, peak flow results, circumstantial activity, and environmental exposure into longitudinal reports. Additional consumer features include automated peak flow monitoring, real-time asthma-zone guidance, personalised pollen reports, an asthma control quiz, and fitness/stress monitoring.
The company also sells a Digital Therapeutics module targeting NHS trusts and private healthcare providers, exposing the same data streams to clinicians and payers for population-level management, early detection of exacerbations, and reduction of hospital admissions. QIoT operates a hybrid B2B2C go-to-market model: a product-led consumer motion via the mobile app with a freemium upgrade path, paired with enterprise field sales (phone and email enquiries) to NHS and private healthcare organisations.
Revenue is generated across four streams: connected device hardware sales, freemium/subscription mobile-app monetisation, annual enterprise subscriptions for the Digital Therapeutics platform, and recurring data-driven insights for healthcare payers. Pricing for enterprise and hardware contracts is quote-based and not publicly disclosed. The company has not disclosed an external equity funding round; capital formation to date appears limited to two Innovate UK prizes, a Scottish Enterprise prize, and Edge and ROCCO innovation awards. Operating status is active, with a 1-10 employee footprint and a UK-centric enterprise geographic scope despite the app's global distribution.
QIoT firmographics
Firmographics- Name
- QIoT
- Legal name
- QIoT Ltd
- Website
- https://qiot.co.uk
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- QIoT is a Scotland-based digital health company offering an AI-powered connected asthma management platform that combines a smart inhaler cap, a freemium mobile app, predictive analytics, and a Digital Therapeutics module for NHS and private healthcare providers.
- Ownership category
- akta.pro rank
QIoT industry classification
Industry- Product category
- Digital Therapeutics
- NAICS
- Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (518)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Medication Adherence & Smart Drug Delivery (Connected Inhalers, Pens, Pill Dispensers) (HLACAPAH)
- akta.pro secondary industries
- Respiratory & Sleep RPM (COPD, asthma, sleep apnea) (HLALAFAB), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL), Edge-Based Clinical Decision Support & Alerts (On-Device/On-Prem Analytics) (HLACAPAL), Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs) (HLALAFAF)
Keywords
Where QIoT is headquartered
LocationHeadquarters
- HQ city
- Paisley
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
QIoT business model
Business model- GTM type
- B2B and B2C
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- Connected Device Sales: QIoT provides connected asthma devices including inhaler caps that record usage, time, and location data. These IoT devices are sold to patients and healthcare providers as part of the solution.
- Mobile Application (Free and Paid Versions): The QIoT app is available in both free and paid for versions on Google Play and Apple Store, suggesting a freemium model with premium features available for purchase.
- Digital Therapeutics Solutions for Healthcare Systems: QIoT offers Digital Therapeutics solutions designed for both the NHS and private healthcare sectors, providing comprehensive platforms for enhanced patient management. This B2B revenue stream involves platform licensing or subscription contracts with healthcare organizations.
- Data-Driven Insights for Payers: The solution provides data-driven insights to healthcare payers, helping them optimise healthcare investments while improving patient outcomes.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Others | Free App Version - Basic asthma management features |
| Subscription | Monthly | Paid App Version - Premium features with enhanced analytics |
| Subscription | Annual | Digital Therapeutics Platform for Healthcare Providers |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels7 records
QIoT product offering
Product offeringCore offering
QIoT provides a Connected Asthma Solution that combines a consumer-facing mobile app (available in free and paid versions) with a proprietary IoT-connected inhaler cap device to capture inhaler usage, time, and location data. The platform applies AI-powered predictive analytics to anticipate asthma exacerbations, integrates peak flow, medication adherence, and environmental exposure data into personalised reports, and offers a separate Digital Therapeutics platform for NHS and private healthcare providers to support patient management and reduce hospital admissions.
Product overview
QIoT offers a single unified product: the QIoT Connected Asthma Solution, which is a comprehensive digital health platform combining a mobile app with connected asthma devices. The core offering includes the mobile app (available in free and paid versions) paired with the Connected Inhaler Cap hardware device. The solution integrates the QIoT AI Healthcare Platform behind the scenes, which employs predictive analytics to anticipate exacerbations. For healthcare professionals, a separate Digital Therapeutics module provides enhanced patient management tools with detailed analytics and real-time monitoring capabilities designed for NHS and private healthcare sectors. The ecosystem includes comprehensive app reports, medication tracking, peak flow monitoring, personalised pollen reports, asthma control quizzes, education resources, and fitness/stress monitoring—all unified within a single app experience.
Differentiator
Problem solved
Functional benefit
Products and services
- QIoT Connected Asthma Solution Mobile App A consumer-facing mobile app (iOS and Android) offered in free and paid versions that enables individuals with asthma to track inhaler usage, peak flow, medication adherence, environmental pollen exposure, and access personalised asthma zone guidance, action plans, and educational resources. Designed for individual patients self-managing their asthma.
- Connected Inhaler Cap An innovative IoT hardware device that attaches to inhalers and records the usage, time, and location of each inhaler activation, helping patients and clinicians identify environmental triggers and monitor medication adherence. Sold to patients and healthcare providers as part of the Connected Asthma Solution.
- Digital Therapeutics Platform for Healthcare Providers An enterprise Digital Therapeutics platform designed for NHS trusts and private healthcare providers, providing detailed analytics, real-time patient monitoring, personalised data-driven asthma care plans, and early detection of exacerbations to reduce hospital admissions and associated costs. Sold via enterprise contracts.
Quantifiable outcome
- 40% of participants went from having daily asthma symptoms to being symptom-free for six or more days
- +2 more outcomes
Companies that use QIoT
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
QIoT technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration8 records
AI capability3 records
Feature7 records
QIoT partnerships and signals
Strategic signalScale indicators3 records
Recent moves5 records
Expansion highlights4 records
QIoT competitors and assessment
Company assessmentDirect peers
- AsthmaMD: AsthmaMD is a mobile asthma tracking app that allows users to log symptoms, triggers, peak flow, and medication use, with physician reporting features. Directly comparable to QIoT's mobile app layer for asthma self-management, though lighter on connected hardware than QIoT's full solution.
- Propeller Health: Propeller Health (acquired by ResMed in 2019) is the leading connected inhaler platform for asthma and COPD, offering sensor attachments, a mobile app, and analytics for patients and providers. Direct overlap with QIoT in connected inhaler hardware, AI-driven analytics, and B2B healthcare payer/provider sales model.
- CareTRx (Teva): CareTRx, originally developed by Gecko Health Innovations and acquired by Teva Pharmaceutical, is a smart inhaler sensor and app for asthma and COPD. Direct competitor to QIoT's connected inhaler cap with similar medication adherence tracking and B2B pharmaceutical partnership model.
- Adherium: Adherium (ASX:ADR) manufactures the Hailie smart inhaler sensor that records medication use and pairs with a mobile app for asthma and COPD management. Directly comparable to QIoT's Connected Inhaler Cap and AI Healthcare Platform, with similar B2B enterprise sales motion to pharmaceutical and healthcare provider partners.
- FindAir: FindAir is a European smart inhaler solution combining a Bluetooth-connected inhaler add-on with a mobile app for asthma patients, focused on medication adherence and trigger identification. Directly comparable to QIoT in product architecture (connected inhaler hardware + app) and EU/UK target market.
Emerging players
- Welltone: Welltone is an early-stage digital therapeutics company building AI-driven respiratory care platforms for asthma and COPD patients, targeting European healthcare providers. Comparable to QIoT in disease focus (asthma), AI predictive analytics approach, and B2B healthcare system deployment model.
- Amiko Respiro: Amiko develops AI-powered connected inhaler sensors and digital therapeutics for respiratory disease, with B2B partnerships across European healthcare systems. Comparable to QIoT in connected inhaler + AI analytics + healthcare system sales motion, with broader European footprint and Series B+ funding.
- Smart Asthma: Smart Asthma is a UK-based mobile app for asthma management focused on personal action plans, symptom tracking, and emergency support. Comparable to QIoT's consumer mobile app offering in UK geography and asthma focus, though without QIoT's connected inhaler hardware component.
Broad incumbents
- myAir (ResMed): myAir is ResMed's consumer app for sleep apnea and COPD patients using ResMed CPAP and ventilation devices, providing personalised coaching and progress tracking. Comparable to QIoT in respiratory patient-facing app model, but broader incumbent with significant device manufacturing scale and FDA-cleared medical device status.
- Vivify Health: Vivify Health is a remote patient monitoring platform covering multiple chronic conditions (cardiac, diabetes, COPD) with mobile apps and integrated device connectivity. Comparable to QIoT's Digital Therapeutics platform layer and B2B NHS-style payer sales motion, but broader condition coverage and larger enterprise footprint.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
QIoT social profiles
Digital presenceQIoT financial estimates
Financial estimateRevenue estimate
Valuation estimate
QIoT leadership team
Management profileNumber of profiles
QIoT funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
QIoT M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about QIoT
What does QIoT do?
QIoT provides a Connected Asthma Solution that combines a consumer-facing mobile app (available in free and paid versions) with a proprietary IoT-connected inhaler cap device to capture inhaler usage, time, and location data. The platform applies AI-powered predictive analytics to anticipate asthma exacerbations, integrates peak flow, medication adherence, and environmental exposure data into personalised reports, and offers a separate Digital Therapeutics platform for NHS and private healthcare providers to support patient management and reduce hospital admissions.
Is QIoT a public or private company?
QIoT is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was QIoT founded?
QIoT was founded in 2018. It employs 1 to 10 people.
Where is QIoT based?
QIoT is headquartered in Paisley, United Kingdom, in the Europe region.
How does QIoT make money?
Four revenue lines are on record. Connected Device Sales are the primary driver. The others are mobile Application (Free and Paid Versions), digital Therapeutics Solutions for Healthcare Systems and data-Driven Insights for Payers.
Who are QIoT's main competitors?
Direct peers on record are AsthmaMD, Propeller Health, CareTRx (Teva), Adherium and FindAir. Emerging players are Welltone, Amiko Respiro and Smart Asthma. Broad incumbents are myAir (ResMed) and Vivify Health.
Does QIoT have an API?
No public API is recorded for QIoT.
What industry is QIoT in?
QIoT's product category is Digital Therapeutics. Its primary akta.pro industry code is HLACAPAH, Medication Adherence & Smart Drug Delivery (Connected Inhalers, Pens, Pill Dispensers), with a secondary code of HLALAFAB, Respiratory & Sleep RPM (COPD, asthma, sleep apnea). Its NAICS code is 518 and its SIC code is 3845.